Pacific International Journal, Vol. 7(1); 2024
ISSN (Print) 2663-8991, ISSN (Online) 2616-4825[1]
DOI: 10.55014/pij.v7i1.556
https://rclss.com/index.php/pij

Overcoming Immune Evasion in CAR-T Cell Therapy: Mechanisms and Coping Strategies for Clonal Evolution in Multiple Myeloma

Hua Li[1], Benben Zhu[1*]

[1]University Cancer Hospital Inner Mongolia Hospital, Hohhot, China
Email: lihuahuanhuan@163.com
[*]Corresponding author:btzhubenben@163.com

Abstract: This paper addresses the issue of immune evasion in CAR-T cell therapy, exploring the mechanisms underlying clonal evolution in multiple myeloma and proposing corresponding coping strategies. Overcoming these challenges necessitates a comprehensive approach, incorporating alternative therapeutic modalities and the advancement of next-generation CAR-T cell therapy. Furthermore, prioritizing in-depth investigations into drug resistance and immune evasion mechanisms, tailoring treatment strategies to individual patients, and conducting clinical trials and regulatory initiatives emerge as key focal points for future research. These endeavors are anticipated to propel the advancement of CAR-T cell therapy in multiple myeloma, offering enhanced treatment prospects for patients.
Keywords: CAR-T cell therapy, immune evasion, multiple myeloma, clonal evolution, mechanisms, coping strategies

1. Introduction

1.1 Background on Multiple Myeloma and CAR-T Cell Therapy

1.1.1 Characteristics of Multiple Myeloma as a Hematologic Tumor

Multiple myeloma is a hematologic malignancy characterized by the abnormal proliferation and accumulation of plasma cells, the antibody-producing cells found in the bone marrow[1]. This condition disrupts the normal functioning of the bone marrow and immune system, leading to a spectrum of clinical manifestations. As a complex and incurable disease, multiple myeloma poses significant challenges to both patients and clinicians. The pathogenesis of multiple myeloma involves the clonal expansion of malignant plasma cells, resulting in the production of excessive and dysfunctional monoclonal immunoglobulins. This aberrant protein production contributes to the development of bone lesions, anemia, renal dysfunction, and immunodeficiency, forming the hallmark features of the disease.

In recent years, advancements in diagnostic techniques and therapeutic modalities have provided a deeper understanding of multiple myeloma's underlying biology and opened avenues for more targeted and personalized treatment approaches. The emergence of novel therapies, including immunomodulatory drugs, proteasome inhibitors, and, notably, chimeric antigen receptor T-cell (CAR-T) therapy, has transformed the landscape of multiple myeloma management. Despite these advancements, challenges persist, particularly in addressing drug resistance and immune evasion phenomena. The intricacies of clonal evolution and the adaptive mechanisms employed by myeloma cells necessitate comprehensive strategies to enhance treatment efficacy and prolong patient survival.

1.1.2 Fundamentals and Application of CAR-T Cell Therapy as a Novel Immunotherapeutic Tool

CAR-T cell therapy, an innovative form of immunotherapy, involves the ex vivo collection of the patient's own T-cells[2]. Through genetic engineering techniques, the CAR (chimeric antigen receptor) gene is introduced into these T-cells, endowing them with the capability to recognize and eliminate specific antigens. These genetically modified CAR-T cells exhibit the ability to identify and target specific antigens present on the surface of multiple myeloma cells.

1.2 The Challenge of immune evasion

While CAR-T cell therapy stands as a groundbreaking cancer treatment, its efficacy in tumors like multiple myeloma is hindered by various challenges. Foremost among them is the formidable issue of immune evasion, significantly constraining the treatment's durability and patients' survival rates.

In the context of immune evasion, tumor cells in patients undergoing CAR-T cell therapy may employ diverse mechanisms to elude the attack of these cells. Strategies include altering surface antigens, inhibiting immune cell activity, and mimicking immune evasion molecules. These evasive mechanisms pose a formidable challenge, hindering CAR-T cells from exerting a sustained and potent killing effect on tumor cells. Consequently, the enduring therapeutic impact is compromised, affecting patient survival.

The existence of these immune evasion challenges poses a substantial hurdle to the clinical application of CAR-T cell therapy. Overcoming these hurdles necessitates intensified research into immune evasion mechanisms and the development of targeted therapeutic strategies.

[Received 12 Dec 2023; Accepted 21 Jan 2024; Published (online) 20, February, 2024]

1.3 Purpose and Significance

The intricate and pivotal realm of clonal evolution mechanisms in multiple myeloma demands thorough exploration, offering invaluable insights for optimizing CAR-T cell therapy. Clonal evolution in multiple myeloma involves the gradual progression of tumor cells from an initial single clone to multiple subclones, engaging in competitive and interactive dynamics. Understanding this complex evolutionary process is crucial for shaping the impact of CAR-T cell therapy in multiple myeloma, underscoring the importance of in-depth research in this area.

2. Literature Review

Chimeric antigen receptor T cell (CAR-T cell) therapy represents a groundbreaking approach in adoptive immunotherapy, involving the engineering of T lymphocytes with synthetic receptors called chimeric antigen receptors (CAR) [3]. Despite its promise, CAR-T cell therapy is not without challenges, as toxicities associated with its clinical application have been discussed by Magee and colleagues. Furthermore, they explore potential clinical interventions to mitigate these toxicities and emphasize the utility of preclinical animal models for predicting the clinical effectiveness of CAR-T cell therapy.

Zhao et al.[4] delve into the applications of CAR-T cells across various hematological malignancies and pave the way for future enhancements in their effectiveness and persistence. Recent advancements in therapeutic engineered T cells, particularly CD19-directed chimeric antigen receptor T cells (CART19), have propelled adoptive T cell immunotherapy into a rapidly growing field within cancer therapy. Notably, Kymriah and Yescarta, both CD19-directed CAR-T cell therapies, have received FDA approval.The combination of CRISPR/Cas9 technology and CAR-T cell therapy holds the potential for further improvements in efficiency and safety[5]. Mollanoori and colleagues review the mechanisms and therapeutic applications of CRISPR/Cas9 technology, its accuracy, and its integration with CAR-T cell therapy, emphasizing its role in enhancing antitumor efficacy.

Safety concerns have tempered the promising efficacy results of CAR-T cell therapy, prompting Grigor et al.[6] to comprehensively summarize the efficacy and safety of CAR-T cell therapy in patients with relapsed or refractory hematologic or solid malignancies. The past decade has witnessed the success of monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and CAR-T cell therapy in hematologic malignancies, as reviewed by Wang et al.[7] . They discuss preclinical and clinical advances in CTLA-4 and PD-L1/PD-1-based ICB and CD19-specific CAR-T cell therapy.Zah et al.[8] address the vulnerability of CAR-T cell therapy to antigen escape and tumor relapse, reporting on the rational design and optimization of bispecific CAR-T cells with robust activity against multiple myeloma resistant to conventional CAR-T cell therapy.Recently, CAR-T cell therapy has garnered approval for aggressive B-cell lymphoma and acute lymphoblastic leukemia, with ongoing research exploring its potential in both hematological and non-hematological diseases[9]. Han et al.[10] highlight the efficacy of CAR-T cell therapy in treating hematological malignancies and offer insights into present research status and trends, focusing on CAR-T technologies, applications, adverse effects, and safety measures.Sterner et al.[11] characterize CAR-T cell therapy as a revolutionary pillar in cancer treatment. They discuss recent innovations in CAR-T cell engineering, aiming to improve clinical efficacy in both hematological malignancies and solid tumors, while addressing limitations associated with this therapy. Shah et al. [12] also contribute to the discourse as an influential work in the field.

3. Impact of Clonal Evolution on CAR-T Cell Therapy

3.1 Influence on Therapeutic Efficacy

The clonal evolution observed in multiple myeloma significantly affects CAR-T cell therapy, particularly in its interference with treatment efficacy. This impact is chiefly manifested in the emergence of diverse clones with distinct phenotypic and genomic profiles. CAR-T cell therapy typically hinges on recognizing and deactivating tumor-specific antigens. However, the presence of clonal heterogeneity introduces a challenge, as certain clones may lack the desired antigens or express mutated antigens. This variation hampers the effective recognition and clearance of tumors by CAR-T cells, thereby impeding the intended therapeutic effect.

3.2 Strategies and Optimization Directions

In light of the aforementioned implications, the following strategies and optimization directions can be considered to address the interference posed by clonal evolution in multiple myeloma on CAR-T cell therapy:

Personalized Treatment Strategy: Develop a personalized treatment plan by comprehensively understanding the clonal heterogeneity and evolutionary trajectory of a patient's tumor. This involves conducting detailed genomic and epigenetic analyses of tumor cells to identify potential targets and resistance mechanisms, enabling the design of more effective CAR-T cell therapies.

Combination Therapy Strategy: Integrate CAR-T cell therapy with other therapeutic modalities, such as targeted drugs, immunomodulators, and radiotherapy, to achieve comprehensive treatment for diverse clones. By combining treatment strategies, the therapeutic coverage can be broadened, the risk of drug resistance development can be mitigated, and overall therapeutic efficacy can be enhanced.

Improvement of CAR Design: Enhance the design of CAR-T cells to accommodate different clonal heterogeneity and antigen expression profiles. This may include introducing CAR-T cells targeting multiple antigens, employing peptide-MHC complex targeting technology, and other advancements aimed at bolstering the adaptability and coverage of CAR-T cells.

In summary, comprehending the impact of clonal evolution in multiple myeloma on CAR-T cell therapy and implementing corresponding strategies and optimization directions can enhance the efficacy and durability of CAR-T cell therapy. This approach can also mitigate the development of drug resistance, thereby positively influencing patient outcomes.

4. Research on immune evasion Mechanisms

4.1 Clonal Evolution Under Immune Stress

Immune stress exerts a profound impact on the clonal evolution of multiple myeloma (MM). The immune system, responsible for maintaining organismal homeostasis by recognizing and eliminating abnormal cells, faces challenges posed by multiple myeloma cells employing various mechanisms to evade and resist immune stress. This facilitates their dominance and clonal evolution under immune selection. The subsequent discourse delineates the effects of immune stress on clonal evolution in multiple myeloma and elucidates the mechanisms enabling clonal cell dominance and escape under immune selection:

4.2 Effects of Immune Stress on Clonal Evolution:

The immune system's role in recognition and clearance plays a crucial part in restricting the development of multiple myeloma clones. Immune cells, such as T cells and natural killer cells (NK cells), play a pivotal role in recognizing and eliminating multiple myeloma cells, inducing immune selection within multiple myeloma clones and fostering the development of immune evasion mechanisms.

4.3 Advantages of Cloned Cells Under Immune Selection:

Multiple myeloma cells, with defects in antigen presentation and processing, can evade recognition by immune cells, conferring a growth and survival advantage under immune selection. These clonal cells can also modify their antigenic expression through mutations and epigenetic modifications, impeding recognition by immune cells. Additionally, they may inhibit immune cell activity and diminish killing effects by producing inhibitory cytokines (e.g., IL-10, TGF-β) and ligands for inhibitory receptors (e.g., PD-1, PD-L1).

Multiple myeloma clonal cells possess the ability to gain an advantage under immune selection and evade immune pressure through diverse escape mechanisms. Understanding and targeting the development of these mechanisms is crucial for investigating therapeutic strategies, including antibody therapies, immune checkpoint inhibitors, and CAR-T cell therapies.

4.4 Immune evasion Mutations in Cloned Cells

Clonogenic cells employ various mechanisms to evade CAR-T cell attacks, including the production of antigenic variants, immune evasion proteins, and immunomodulatory factors. The subsequent section provides a detailed exploration of these evasion mechanisms:

4.4.1 Antigenic Mutation:

Clonal cells can evade CAR-T cell attacks by producing antigenic mutations, inducing structural changes in antigens initially recognized by CAR-T cells. This renders CAR-T cells ineffective in recognizing and eliminating these mutated clonal cells.

4.4.2 immune evasion Proteins:

Clonal cells may produce immune evasion proteins that interfere with CAR-T cell function. For instance, overexpression of PD-L1 in clonal cells can bind to PD-1 on CAR-T cells, allowing the clonal cells to escape killing by inhibiting CAR-T cell activity.

4.4.3 Immunomodulatory Factors:

Clonal cells can produce immunomodulatory factors, such as immunosuppressive cytokines (e.g., IL-10 and TGF-β), which reduce the activity of CAR-T cells, limiting their ability to attack clonal cells.

In conclusion, clonal cells evade CAR-T cell attacks through antigenic variants, immune evasion proteins, and immunomodulatory factors. Understanding and overcoming these escape mechanisms are pivotal to enhancing the efficacy and durability of CAR-T cell therapy. Researchers are actively developing strategies to target these mechanisms, including combining therapeutic approaches, inhibiting immunosuppressive molecules, and modulating the immune environment, with the goal of enhancing the effectiveness of CAR-T cell therapy.

5. Coping Strategies and Progress in Treatment

5.1 Predicting and Monitoring Drug Resistance and immune evasion

The anticipation and monitoring of tumor cell resistance and immune evasion stand as pivotal facets of personalized cancer therapy. The ensuing discussion outlines various methods and techniques employed for predicting and monitoring drug resistance and immune evasion:

5.1.1 Genomic Analysis:

High-throughput sequencing analysis of tumor samples, encompassing whole-genome, whole-exome, or genome rearrangement, facilitates the identification of mutations, protein expression, and gene alterations linked to immune evasion. This data can predict drug treatment efficacy, pinpoint potential drug resistance mutations, and assess the immune evasion potential of clonal cells.

5.1.2 Single-Cell Technology:

Utilizing single-cell sequencing technology enables the analysis of intra-tumor heterogeneity, unveiling drug-resistant mutant subclones and immune evasion cell subpopulations. This technology tracks the dynamics of drug-resistant subclones, characterizes the phenotype and function of immune evasion cells, providing more precise information for individualized therapy.

5.1.3 Immune Cell Testing:

Monitoring immune cells in the patient's peripheral blood or tumor tissue allows assessment of the immune response and detection of conditions such as an increase in immunosuppressive cells, cytokine secretion, among others.

5.1.4 Microenvironmental Analysis:

A comprehensive analysis of immune cell infiltration extent, cytokine and signaling pathway activation status, and expression of immunomodulatory molecules in the tumor microenvironment aids in predicting tumor response to immunotherapy and uncovering potential immune evasion mechanisms and drug resistance development.

5.1.5 Liquid Biopsy:

Analyzing circulating tumor DNA, extracellular vesicles (EVCs), and circulating tumor cells (CTCs) in the blood enables the monitoring of tumor resistance and immune evasion, allowing timely adjustments to treatment regimens.

5.1.6 Functional Cell Analysis:

Functional analysis techniques, including immune cell function assays and cytotoxicity assays, evaluate the function and activity of immune cells, shedding light on the mechanisms of clonal cell escape from immune cells.

The integrated application of these methods and technologies forms a crucial foundation for individualized adjustment and intervention in cancer treatment. Timely monitoring of drug resistance and immune evasion empowers physicians to modify treatment regimens, encompassing drug switches, combination therapies, and adjustments to immunotherapy regimens, thereby enhancing therapeutic efficacy and mitigating drug resistance development.

5.2 Combined Application with Other Treatments

The integration of additional treatments proves instrumental in overcoming drug resistance and immune evasion in CAR-T cell therapy. The following strategies are commonly employed:

5.2.1 Targeted Therapy Combined with CAR-T Cell Therapy:

Targeted therapeutic agents selectively interfere with cancer cell proliferation, survival, or specific signaling pathways, thereby augmenting the effectiveness of CAR-T cell therapy. For instance, the selective inhibition of immune evasion-related signaling pathways (e.g., PD-1/PD-L1 or CTLA-4) through specific targeting agents enhances CAR-T cells' ability to kill clonal cells, improving therapeutic efficacy.

5.2.2 Application of Immunomodulators:

Immunomodulators can adjust the tumor microenvironment, amplify the activity of immune cells, and enhance CAR-T cells' capacity to eliminate clonal cells. Immune checkpoint inhibitors (e.g., PD-1/PD-L1 or CTLA-4 inhibitors) stimulate immune cell activity, boosting the antitumor effects of CAR-T cells.

5.2.3 Application of Combination Therapy:

The integration of multiple treatments, including chemotherapy, radiation, or other immunotherapies, allows for a multifaceted assault on tumors, reducing the risk of drug resistance and escape. Tailored combination therapies, adapted on an individual basis, consider factors such as tumor type, resistance mechanisms, and overall condition.

5.2.4 Improvements in CAR-T Cell Design:

Enhancements in the structure and function of CAR-T cells play a pivotal role in overcoming drug resistance and immune evasion. For instance, introducing multiple antigen recognition domains (CARs), additional signaling molecules, and co-stimulatory molecules can heighten CAR-T cells' activity, enabling the recognition of more antigens and enhancing the tumor-killing effect under immune evasion mechanisms.

It is imperative to underscore that the selection of strategies for addressing drug resistance and immune evasion in CAR-T cell therapy should be made on a case-by-case basis, considering unique aspects of each tumor type. The combined utilization of multiple therapies has the potential to elevate treatment efficacy and diminish the occurrence of drug resistance and escape. Ongoing studies and clinical trials are necessary to validate the efficacy and safety of these strategies.

5.3 Improving the Design and Engineering of CAR-T Cell Therapy

In response to the inherent limitations of CAR-T cell therapy, researchers and clinicians persistently explore and refine strategies to enhance cell activity and tolerance. The ensuing strategies represent common avenues of improvement:

5.3.1 Introduction of Anti-Tumor Genes:

Beyond the conventional CAR structure, the incorporation of anti-tumor genes, such as those inhibiting tumor proliferation or enhancing immune activity, augments the tumor-killing prowess of CAR-T cells. For instance, gene editing technology can introduce cytokine genes like IL-12, IL-18, or CCL19 to boost the survival and activity of CAR-T cells in the tumor microenvironment, thereby enhancing therapeutic efficacy.

5.3.2 Modification of the CAR Structure:

Structural modifications to CAR involve broadening the antigen recognition range, amplifying signaling, and refining adaptability to bolster the activity and tolerance of CAR-T cells. Designing CAR-T cells with multiple antigen recognition

domains improves recognition and killing of diverse tumor antigens. Additionally, modifying co-stimulatory molecules, such as introducing CD28 and 4-1BB, enhances the activity and viability of CAR-T cells.

5.3.3 Introduction of Safety Switches:

Incorporating safety switches enhances CAR-T cell safety by facilitating control or removal in the event of severe toxic effects or other safety concerns. Genetic switches (e.g., iCaspase9) or drug-induced safety switches (e.g., Receptor Kinase Residue Immunity Global Receptor T Cells - RQR8) can be introduced to trigger CAR-T cell apoptosis when necessary.

5.3.4 Applications of Cellular Synthetic Biology:

Leveraging synthetic biology enables the design of CAR-T cells that respond more precisely to the tumor microenvironment, improving therapeutic efficacy and reducing toxic side effects.

5.3.5 Introduction of Tolerant Cells:

Introducing modified tolerogenic cells into CAR-T cell therapy mitigates activity loss due to chronic stimuli and tumor suppressors. All these strategies aim to enhance the therapeutic efficacy of CAR-T cells, improve adaptation to the tumor microenvironment, and enhance safety. While these innovative approaches hold promise for the future of CAR-T cell therapy, further clinical studies are imperative to validate their safety and efficacy.

6. Conclusion and Outlook

6.1 Knowledge and Reflections on immune evasion in CAR-T Cell Therapy

While direct access to specific papers is unavailable, reflections on drug resistance and immune evasion in CAR-T cell therapy are offered based on common ideas and research findings in the field.

6.1.1 Current Perspectives on immune evasion in CAR-T Cell Therapy:

Researchers widely acknowledge the complexity of resistance mechanisms in CAR-T cell therapy. Studies indicate that drug resistance involves various factors, including alterations in targeted antigen expression, activation of immune evasion pathways, and the establishment of an immunosuppressive microenvironment. The amalgamation of these mechanisms enables tumor cells to evade recognition and attack by CAR-T cells, thereby diminishing therapeutic efficacy. The importance of combination treatment strategies is a consensus among researchers addressing immune evasion. Combining other therapeutic approaches, such as targeted therapies and immunomodulators, is seen as crucial to enhance the effectiveness of CAR-T cell therapy and counter potential immune evasion mechanisms.

The prospects of next-generation CAR-T cell therapeutics, involving the introduction of anti-tumor genes, modification of CAR structure, and bispecific CAR-T cells, are continuously explored. These innovative strategies aim to improve CAR-T cells' ability to recognize and attack tumors, addressing the challenge of immune evasion.

6.1.2 Outlook and Consensus Among Researchers:

The consensus points towards the development of personalized therapeutic strategies, reflecting a deeper understanding of immune evasion mechanisms. Future therapeutic directions are anticipated to be more tailored to individual patient profiles.

In summary, immune evasion remains a focal point of research in CAR-T cell therapy. Solving these challenges demands comprehensive therapeutic strategies and continuous innovation in CAR-T cell therapy methods. A deeper understanding of these issues, coupled with the development of new therapeutic strategies, holds the promise of bringing hope and breakthroughs for the future of CAR-T cell therapy. In the realm of multiple myeloma, CAR-T cell therapy shows promising application prospects. Continuous exploration and practice in the aforementioned directions are expected to broaden the application of CAR-T cell therapy in multiple myeloma patients, providing more effective treatment options for this hematological tumor. This development holds the potential to improve the survival quality and prognosis of patients.

References:

[1] Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., ... & Ajebo, G. H. (2021). Epidemiology, staging, and management of multiple myeloma. Medical Sciences, 9(1), 3.

[2] Hartmann, J., Schüßler-Lenz, M., Bondanza, A., & Buchholz, C. J. (2017). Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts. EMBO molecular medicine, 9(9), 1183-1197.

[3] Michael S Magee; Adam E Snook; "Challenges To Chimeric Antigen Receptor (CAR)-T Cell Therapy For Cancer", DISCOVERY MEDICINE, 2014. (IF: 4)

[4] Z. Zhao, Y. Chen, N. M. Francisco, Y. Zhang, and M. Wu, "The Application Of CAR-T Cell Therapy In Hematological Malignancies: Advantages And Challenges," Acta Pharmaceutica Sinica. B, 2018.

[5] H. Mollanoori, H. Shahraki, Y. Rahmati, and S. Teimourian, "CRISPR/Cas9 And CAR-T Cell, Collaboration Of Two Revolutionary Technologies In Cancer Immunotherapy, An Instruction For Successful Cancer Treatment," Human Immunology, 2018.

[6] E. J. M. Grigor, D. Fergusson, N. Kekre, J. Montroy, H. Atkins, M. D. Seftel, M. Daugaard, J. Presseau, K. Thavorn, B. Hutton, R. A. Holt, and M. M. Lalu, "Risks And Benefits Of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy In Cancer: A Systematic Review And Meta-Analysis," Transfusion Medicine Reviews, 2019.

[7] H. Wang, G. Kaur, A. I. Sankin, F. Chen, F. Guan, and X. Zang, "Immune Checkpoint Blockade and CAR-T Cell Therapy in Hematologic Malignancies," Journal Of Hematology & Oncology, 2019.
[8] E. Zah, E. Nam, V. Bhuvan, U. Tran, B. Y. Ji, S. B. Gosliner, X. Wang, C. E. Brown, Y. Y. Chen, "Systematically Optimized BCMA/CS1 Bispecific CAR-T Cells Robustly Control Heterogeneous Multiple Myeloma," Nature Communications, 2020.
[9] I. Los-Arcos, G. Iacoboni, M. Aguilar-Guisado, L. Alsina-Manrique, C. Díaz de Heredia, C. Fortuny-Guasch, I. García-Cadenas, C. García-Vidal, M. González-Vicent, R. Hernani, M. Kwon, M. Machado, X. Martínez-Gómez, V. Ortiz Maldonado, C. Pinto Pla, J. L. Piñana, V. Pomar, J. L. Reguera-Ortega, M. Salavert, P. Soler-Palacín, L. Vázquez-López, P. Barba, I. Ruiz-Camps, "Recommendations for Screening, Monitoring, Prevention, and Prophylaxis of Infections in Adult and Pediatric Patients Receiving CAR T-cell Therapy: A Position Paper," Infection, 2020.
[10] D. Han, Z. Xu, Y. Zhuang, Z. Ye, and Q. Qian, "Current Progress in CAR-T Cell Therapy for Hematological Malignancies," Journal Of Cancer, 2021.
[11] R. C. Sterner and R. M. Sterner, "CAR-T Cell Therapy: Current Limitations and Potential Strategies," Blood Cancer Journal, 2021.
[12] N. N. Shah, T. Maatman, P. Hari, and B. Johnson, "Multi Targeted CAR-T Cell Therapies For B-Cell Malignancies," Frontiers In Oncology, 2019.